![]() ![]() ![]() A great deal of work is involved in taking a picture captured by an X-ray or MRI machine and getting it ready for a radiologist to read, including being sure it is a high-quality image and properly formatted and rotated. As reported a few years ago by the Mayo Clinic, commercial facial recognition software can be used to identify people from brain MRIs that includes imagery of the face, despite steps that researchers typically take to protect patient privacy.Ĭlario is also actively working on solutions using AI to automate the laborious image preparation process, says Thomas. “Even if we have a human that is double-checking the whole video, it is a lot faster to check the AI’s work than to be going in and blurring out the faces in every video frame.”Īlong the same lines, Thomas says, Clario will soon be rolling out software in a clinical trial to blur faces in brain MRIs while maintaining the integrity of the imaging data for evaluating the health of study participants. One major use of AI currently is in support of the image redaction process in studies involving video footage of study participants, both to protect patient privacy and eliminate the time-intensive step of manually obscuring their faces, Thomas adds. The solution scans documents and flags all identified PHI, but people doing the redaction independently decide what does and does not get redacted, Jones says. If a human misses PHI in the redaction process, the study sponsor, the CRO, and the software provider could be penalized millions of dollars-not to mention the incalculably high cost of a bad reputation.ĪI is already being used to detect possible PHI in text information captured in clinical trials, including identifiers such as date of birth and medical record number referenced in physician notes and PDFs (e.g., lab values, discharge summaries, and CT scan results). Together with Łukasz Kidziński, Ph.D., co-director of AI at Clario, their talk will cover imaging and source document redactions as well as electronic clinical outcome assessment (eCOA) in decentralized clinical trials.Ī lot of attention has been paid to protecting personal health information (PHI) because a breach could be potentially catastrophic, she notes. 10, the final day of the 2022 Summit for Clinical Ops Executives (SCOPE). Thomas and Jones will be presenting on the use of AI to improve clinical trial efficiencies on Feb. Thomas was at the time serving as CEO of Saliency. Those efforts picked up steam earlier last year when then-Bioclinica acquired Saliency and began integrating the company's advanced AI technology into its imaging platform, says Jones. “Anywhere we can implement AI to do that is what we want to do.” The result is faster, more efficient clinical trials with less of the bias associated with purely manual evaluations while sidestepping the potential risks of AI.ĪI-enabled applications at Clario are designed to “help prevent humans from errors or creating errors,” adds Janine Jones, senior product manager for adjudication and eligibility. “Our partnership enables patients in China to participate in clinical trials testing novel neurodegenerative disease therapeutics.Janu| Acceptance of artificial intelligence (AI) in clinical research is on the rise thanks, in part, to its pairing with human expert oversight, according to Kevin Thomas, Ph.D., co-director of AI at Clario, the technology company born of the recent merger of ERT and Bioclinica. "XingImaging is proud to be working with Clario in providing PET imaging multi-center clinical trials,” said Gilles Tamagnan, CEO XingImaging, LLC. “Our continued partnership with XingImaging is advancing therapeutics in APAC.” “Broadening our scope of clinical trials to further support drug development in neuroscience presents a unique opportunity for both patients and clinical researchers,” said Joyce Suhy, PhD, SVP Medical Imaging at Clario. The new expanded offering leverages the joint resources and neuroscience experts of Clario and XingImaging to expedite the startup of clinical trials and drug discovery in China, including amyloid, tau, and other targets. A dedicated team of neuroscientists and project managers have led multiple trials in China to date. PET imaging has supported novel studies for Alzheimer's disease (AD) and other neurodegenerative diseases. JanuClario, a technology company that delivers the leading endpoint technology solutions for clinical trials, and XingImaging, a radiopharmaceutical production and positron emission tomography (PET) acquisition company, have expanded their partnership to deliver PET imaging clinical trials for testing novel therapeutics in China.Ĭlario, formerly ERT and Bioclinica, and XingImaging joined forces in 2018 to support multi-center clinical trials requiring PET for eligibility and drug efficacy evaluation. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |